Psychiatric diagnosis has a precision problem. Conditions like schizophrenia and bipolar I disorder are often misdiagnosed, delayed, or confused with each other, sometimes for years. Now, a new approach is trying to bring objective biology into the equation.
Laguna Diagnostics, LLC has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its mRNA Gene Biomarker Test, a blood-based tool designed to differentiate between schizophrenia and bipolar I disorder.
Unlike most areas of medicine, psychiatry still relies heavily on:
For two conditions with overlapping symptoms, but very different management strategies—this is a serious problem.
Laguna’s approach is rooted in biology, not just behavior.
Important: This is not a standalone diagnostic. It is designed to support clinical decision-making, not replace it.
As part of the Breakthrough Device process, Laguna reanalyzed its pivotal study using a locked algorithm.
These numbers suggest a highly discriminative biological signal, a rare claim in psychiatric diagnostics.
The FDA’s Breakthrough Devices Program is designed to fast-track technologies addressing serious conditions.
In short: faster pathway, same bar.
If validated, this test could shift how psychiatry operates.
This is especially important because:
Laguna is part of a broader movement toward data-driven mental healthcare.
This mirrors what has already happened in:
Psychiatry has lagged—until now.
Laguna is still in the validation and development phase.
The company is also refining its platform to expand beyond these two disorders.
Laguna’s mRNA biomarker test tackles one of the most persistent problems in mental healthcare: diagnostic uncertainty.
The promise is clear:
But the risks are equally real:
If the data holds up through larger validation studies, this could mark a turning point for precision psychiatry. If not, it will join a long list of promising—but ultimately limited—biomarker tools in mental health. Either way, this is a space worth watching closely.